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30% of the pairs, group assignment was discrepant, implying a different therapeutic decision. In some
dogs certain circumstances (e.g. excessive barking, difficulties during blood collection, excitement at
arrival) were identified as potential factors explaining the discrepancy between prepill 1 and 2 cortisol
measurements. CONCLUSIONS: In a substantial number of dogs treated with trilostane, the two prepill
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Abstract
Background: The ideal method for monitoring trilostane therapy in dogs with hypercortisolism is still open to
debate. Recently, determination of the pre-trilostane (prepill) cortisol concentration has been proposed to be more
repeatable than either post-trilostane or post-ACTH cortisol. The aim of this study was to compare two prepill
cortisol concentrations in dogs with hypercortisolism during trilostane therapy. Sixteen client-owned dogs with
naturally occurring hypercortisolism were prospectively included and cortisol concentrations were measured twice,
1 h apart, before the morning trilostane dose (prepill 1 and 2 cortisol).
Results: A total of 47 prepill cortisol measurement pairs were included. Compared to prepill 1, prepill 2 cortisol was
higher in 15, equal in 8 and lower in 24 pairs. Group agreement between prepill 1 and 2 cortisol was 70%
(moderate agreement - weighted kappa 0.55). In 30% of the pairs, group assignment was discrepant, implying a
different therapeutic decision. In some dogs certain circumstances (e.g. excessive barking, difficulties during blood
collection, excitement at arrival) were identified as potential factors explaining the discrepancy between prepill 1
and 2 cortisol measurements.
Conclusions: In a substantial number of dogs treated with trilostane, the two prepill cortisol concentrations
differed. Part of this difference might be ascribable to stressful events during test performance. When using prepill
cortisol measurements to monitor trilostane therapy, recording of any incident during handling that might affect
cortisol release might be helpful to make a reliable decision about a trilostane dose adaptation.
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Background
For a long time, the ACTH stimulation test has been
considered the method of choice for monitoring trilos-
tane therapy in dogs [1–6]. As trilostane is short-acting
and shows its main effects a few hours after application,
the results of the ACTH stimulation tests are largely
dependent on the time between the last trilostane appli-
cation and test administration [4, 7, 8]. Possibly over-
dosed dogs with baseline and post-ACTH cortisol
concentrations < 2 μg/dl 3–6 h after trilostane applica-
tion had a significantly higher cortisol concentration if
the test was repeated 6 h later [8]. Continuing trilostane
therapy without reducing the trilostane dose did not in-
duce clinical hypoadrenocorticism and seemed safe in
the majority of these dogs [8]. This raised serious con-
cerns about the reliability of the ACTH stimulation test
as a monitoring tool. In addition, in recent years, the
availability of synthetic ACTH has been limited and, in
some countries, a major price increase has occurred.
Moreover, at high concentrations, synthetic ACTH
causes adrenal damage in rats [9]. Although, low doses
of ACTH (1 μg/kg) can be used in dogs receiving trilos-
tane [10], a monitoring method not relaying on ACTH
would be preferable. In several studies baseline cortisol,
endogenous ACTH, cortisol/ACTH ratio, haptoglobin,
urine corticoid:creatinine ratio (UCCR) and clinical signs
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reported by owners were evaluated, but none of them
seemed convincingly superior to the ACTH stimulation
test [11–16]. A recent study compared the pre-trilostane
cortisol, the three-hour post-trilostane cortisol and the
post-ACTH cortisol concentrations against the clinical
signs reported by owners [17]. This study showed that
the pre-trilostane and the three-hour post trilostane cor-
tisol concentrations were potentially better monitoring
parameters than the post-ACTH cortisol concentrations,
as they differentiated better between dogs with excellent
control and dogs that were inadequately controlled [17].
In addition, a further study by the same group showed
that the pre-trilostane cortisol concentration is more re-
peatable than the post-trilostane or the post-ACTH cor-
tisol concentration in dogs on a constant dose of
trilostane [18]. Therefore, measurement of one cortisol
value just before the next trilostane application seemed a
potentially more reliable assessment of treatment control
in trilostane-treated dogs, and one, which might replace
the ACTH stimulation test.
The question remains, however, whether one single
cortisol measurement in trilostane-treated dogs with
hypercortisolism (HC) is sufficiently reliable. It is well
known that cortisol concentrations fluctuate and are in-
fluenced by various factors, e.g. stress [19]. The
agreement between two cortisol measurements taken
within an hour of each other in dogs with HC and
treated with trilostane, has never been evaluated. There-
fore, the aim of this study was to investigate the agree-
ment of two prepill cortisol measurements in dogs with
HC during trilostane therapy.
Results
Comparison of prepill 1 and 2 cortisol measurements
A total of 47 cortisol measurement pairs from 16 dogs
were included, with 13 of the dogs providing multiple
pairs (2 pairs (5 dogs), 3 pairs (3 dogs), 4 pairs (1 dog), 5
pairs (3 dogs), 6 pairs (1 dog)). The length of trilostane
therapy ranged from 2 to 36 weeks (median: 12). Prepill
1 cortisol ranged from 0.8 to 21 μg/dl (median: 4.7) and
prepill 2 cortisol from 1.1 to 18.1 μg/dl (median: 4.8) (p
= 0.18, 1-β = 0.2). (Fig. 1a). Compared to prepill 1 corti-
sol, prepill 2 cortisol was higher in 15 pairs, equal in 8
pairs and lower in 24 pairs (Fig. 1b and c).
Group agreement
Group agreement between prepill 1 and prepill 2 cortisol
was observed in 33/47 (70%) pairs and disagreement in
14/47 (30%) pairs (moderate agreement, weighted kappa
0.55 [20]) (Table 1).
CB
A
Fig. 1 Scatter plot of prepill 1 and prepill 2 cortisol concentrations: a - absolute values for all cortisol pairs (n = 47); b - course of the two prepill
cortisol concentrations in pairs in which both values were allocated to the same group according to the target range (1.5–5 μg/dl; n = 33); c -
course of the two prepill cortisol concentrations in pairs in which the two cortisol values were not allocated to the same group (n = 14). The grey
area represents the defined cortisol target range
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In eight cortisol pairs at least one value was below the
target range (1.5–5 μg/dl) and in 3 (37.5%) of these, both
values were below the target range (Fig. 2a+b, Table 1).
In 26 cortisol pairs at least one value was within the
target range and in 13 (50%) of these, both values were
within the target range (Table 1).
Finally, in 27 pairs at least one cortisol value was
above the target range and in 17 (63%) of these, both
values were above the target range (Table 1).
Follow-up of dogs with values below the target range
In five cortisol pairs one value was below and the second
value within or above the target range (Fig. 2a). These
cortisol pairs belonged to five different dogs.
In four of them, the trilostane dose was not changed,
as none showed signs of hypocortisolism. All four dogs
returned to our clinic after 1, 2, 3 or 6 months, respect-
ively. At that time, none of these dogs showed prepill
cortisol values below the target range. In dog five, the
trilostane dose was decreased. This dog did not show
clinical signs of hypocortisolism at that point, but had
had three cortisol pairs with both values below the target
range at the three previous visits (see below).
In three cortisol pairs, both values were below the tar-
get range (Fig. 2b). All three pairs belonged to dog five
mentioned above. The dog never showed signs of hypo-
cortisolism. The trilostane dose was gradually reduced
from 1.7 mg/kg/d to 0.38 mg/kg/d. In this dog, trilostane
was discontinued 6months after the last re-evaluation
included in this study. Further re-evaluations 1 and 4
months after cessation of trilostane therapy did not re-
veal recurrence of clinical signs of HC; the dog remained
clinically healthy without any medications.
Factors explaining differences between paired
measurements
In several dogs certain circumstances (e.g. excessive
barking during hospitalization, difficulties during blood
collection, severe excitement during arrival) could be
identified as potential factors explaining the differences
between some paired prepill 1 and 2 cortisol measure-
ments (Fig. 3).
Discussion
The main goal of this study was to compare two prepill
cortisol concentrations in dogs with HC during trilostane
therapy. Although, the two cortisol values (prepill 1 and
prepill 2) did not differ significantly, total group agree-
ment between the two concentrations was only moderate,
meaning that in 30% of the dogs there was a substantial
difference between the two measurements. This led to a
different group allocation according to the target range
and possibly to differing therapeutic decisions.
Dogs with prepill cortisol concentrations below the target
range are most critical, as overtreatment has to be identified
and iatrogenic hypoadrenocorticism excluded. It is known
Table 1 Group agreement between prepill 1 and 2 cortisol concentrations
Prepill 2 cortisol (< 1.5 μg/dl) Prepill 2 cortisol (1.5–5 μg/dl) Prepill 2 cortisol (> 5 μg/dl)
Prepill 1 cortisol (< 1.5 μg/dl) 3 1 1
Prepill 1 cortisol (1.5–5 μg/dl) 3 13 5
Prepill 1 cortisol (> 5 μg/dl) 0 4 17
Weighted Kappa = 0.55
A
B
Fig. 2 Course of prepill 1 and prepill 2 cortisol concentrations for
specific cortisol pairs: a - all pairs in which one value was below the
target range of the study. b - all pairs in which both values were
below the target range of the study. The grey area represents the
defined cortisol target range
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that many dogs with low cortisol concentrations a few
hours after trilostane application (around the time of max-
imal trilostane action) do not show clinical signs of hypo-
cortisolism [8, 17]. In addition, low post-ACTH cortisol
concentrations 2–3 h after trilostane application may not
persist, but increase significantly when the test is repeated a
few hours later and when the effect of trilostane action is
tailing off [8]. In contrast, a low prepill cortisol concentra-
tion was postulated to more reliably point towards exces-
sive suppression, as this would be about 12 h after the last
dose of trilostane [17]. Our study, now, shows that even at
that time point cortisol fluctuations occur, possibly leading
to discrepant results. In 5 of 8 cortisol pairs with cortisol
concentrations below the target range, the second value
was within or even above the defined cortisol target range.
We hypothesize that dogs like this are not at high risk of
developing clinically relevant hypoadrenocorticism. A re-
duction of the trilostane dose in these dogs might lead to
less control of disease due to a increase in cortisol concen-
trations. Follow-up of our dogs appeared to verify this hy-
pothesis, as in 4/5 dogs the trilostane dose was not
decreased and none of them developed signs of HC. If both
prepill cortisol concentrations are below the target range,
we hypothesize that overtreatment cannot be excluded. In
this situation, the authors would opt for a dose reduction to
avoid the risk of clinical hypocortisolism. In case of (subtle)
clinical signs of hypocortisolism (tiredness, reduced appe-
tite) starting glucocorticoid therapy should be considered.
In three cortisol pairs in our study both values were below
the target range. All three pairs belonged to the same dog.
Clinically, this dog never showed signs of hypocortisolism,
but the trilostane dose was gradually decreased and finally
stopped. As the number of dogs included in our study is
low, it is difficult to draw definitive conclusions how to
proceed if discrepant results occur. The above-mentioned
hypothesis, about the risk of developing hypocortisolism in
dogs with low prepill cortisol values, should therefore be
evaluated in further studies with a larger number of
animals.
In some dogs with a substantial difference between the
two cortisol values, the discrepancy could be ascribed to
certain occurrences during evaluation. These events
were: excessive barking during the one hour waiting
time, problems drawing blood at prepill 1 or 2 cortisol
measurements and severe excitement upon arrival. It
has already been shown that examination and
hospitalization can increase the urine cortisol to creatin-
ine ratios [21]. Influence from environmental stress (e.g.
by travelling to the hospital) has also been suggested to




Fig. 3 Values of prepill 1 and prepill 2 cortisol concentrations in three dogs (a-c). Dog A: stayed in the hospital at 1st re-evaluation (RE), barking
the whole time. At the 2nd and 3rd RE the dog went home with owner. Constant trilostane dose of 1 mg/kg BID for all REs. Dog B: Difficulties at
1st RE in drawing blood for prepill 1; no problems drawing blood for prepill 2. No problems drawing blood at 2nd RE. Constant trilostane dose of
1 mg/kg BID for both REs. Dog C: Dog always very excited upon arrival. Stays in the hospital at each RE and calms down. Increasing trilostane
doses between 1st and 4th RE (1.3–3.3 mg/kg BID). The grey area represents the defined cortisol target range
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As the occurrence of such stress factors was not pro-
spectively assessed or recorded during the study, we cannot
exclude that other events occurred, possibly explaining fur-
ther discrepant results. In addition, as there is no clear
marker for stress in dogs, severe stress could even go
unrecognized. Both values can be influenced by stress, and
neither prepill 1 nor prepill 2 cortisol concentration seems
clearly better than the other. However, the recording of any
incident during arrival, clinical hospitalization and handling
of the dog seems important to be able to later relate the
values to an event and help in their interpretation.
Dogs, which have one value within the target range,
but the other above the target range should also be dis-
cussed. If only the higher value had been measured, the
trilostane dose would have been increased. In contrast, if
only the value within the target range had been mea-
sured, the trilostane dose would not have been altered.
Which treatment decision would be correct has to be
evaluated in future studies.
One limitation of this study is the rather low sample
size and therefore a low power of the statistical test.
Therefore, our results can only be regarded as prelimin-
ary and should be confirmed in a larger study. Other
limitations included the lack of prospective assessment
and documentation of stressful events and the lack of a
validated, standardized clinical score, to which the corti-
sol results can be compared. Finally, the lack of a con-
current ACTH stimulation test could also be judged as
limitation. However, the goal of this study was not to as-
sess the prepill cortisol as a monitoring tool and com-
pare it to the post-ACTH cortisol, but to investigate the
agreement between two prepill cortisol measurements.
Conclusions
The agreement between two prepill cortisol concentra-
tions taken one hour apart and 11–13 h after the last tri-
lostane application is only moderate. Stressful events
occurring during the re-evaluation can influence both
cortisol concentrations. It is advisable to record any inci-
dent during handling of the dog, to possibly later relate
the cortisol values to an event and help in their inter-
pretation. Even though determination of two prepill cor-
tisol values instead of one may lead to discrepant results,
the additional information gained from two instead of
one cortisol value can be helpful for the decision about a
trilostane dose adaptation. In dogs in which both prepill
cortisol concentrations are below the target range, a tri-
lostane dose reduction should be considered.
Methods
Animals
Sixteen dogs with naturally occurring HC were prospect-
ively enrolled. Eleven dogs were male (6 castrated) and 5
were female (5 spayed). Breeds included Bergamasco
Sheepdog (1), Berger Blanc Suisse (1), Chihuahua (1),
French Bulldog (1), Lapinkoira (1), Maltese dog (2), Petit
Basset Griffon Vendéen (1), Podengo Português (1),
Standard poodle (1), Yorkshire Terrier (4), and 2
mixed-breed dogs. Age ranged between 6 and 16 years
(median 10) and body weight between 5 and 30 kg (me-
dian 10). The criteria for inclusion were clinical signs
consistent with HC (e.g. polyuria, polydipsia, polyphagia,
panting, skin problems, weakness, abdominal enlarge-
ment), a positive low-dose dexamethasone test (LDDS
test) or a positive ACTH stimulation test and the agree-
ment of the owner to treat the dog with trilostane
(Vetoryl, MSD Animal Health GmbH, Lucerne,
Switzerland) and to present it for regular re-evaluations.
The inclusion of the dogs in the study was approved by
the veterinary office of the canton of Zurich and was in
accordance with the guidelines and directives established
by the Animal Welfare Act of Switzerland (TVB 191/
13). Written consent of all pet owners was obtained be-
fore including the dogs in the study.
Experimental design
The prospective study was performed between Septem-
ber 2016 and March 2017 at the clinic for Small Animal
Internal Medicine of the University of Zurich. Only dogs
on twice-daily trilostane therapy were included. The
starting dose of trilostane for dogs with HC was 0.5–1
mg/kg q12h. Every dog was included independent on
the length of the previous trilostane therapy. At each
re-evaluation, cortisol concentrations were measured
twice, 1 h apart, just before the morning trilostane dose
(prepill 1 and prepill 2 cortisol). Blood was drawn ap-
proximately 11–12 h after the last trilostane application
for prepill 1 and 12–13 h after the last trilostane applica-
tion for prepill 2. The target ranges of both cortisol con-
centrations were defined as 1.5–5 μg/dl [16]. Every dog
was assessed by a standardized owner questionnaire and
by a clinical examination. The trilostane dose was ad-
justed according to the prepill cortisol concentrations
and the clinical signs.
For the group agreement analysis, each prepill cortisol
concentration was assigned to one of three groups accord-
ing to the control of cortisol release: cortisol < 1.5 μg/dl
(excessive control), cortisol 1.5–5 μg/dl (adequate control)
or cortisol > 5 μg/dl (inadequate control).
Analytical procedures
Serum was stored at − 20 °C until assayed. Serum cortisol
concentrations were measured by a competitive immuno-
assay (DPC Immulite® 2000, Siemens Schweiz AG, Zurich,
Switzerland), previously validated in dogs and performed
according to manufacturer’s instruction, at a commercial la-
boratory [22]. The accuracy of the methodologies was
assessed by continuous yearly participation in an external
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quality assurance program, ESVE Veterinary Endocrinology
External Quality Assessment Scheme (VEEEQADS). As
stated by the manufacturer, the intra-assay coefficients of
variation were 10 and 6% at cortisol levels of 2.7 and
18.9 μg/dl, respectively. Therefore, prepill 1 and 2 cortisol
concentrations differing ≤10% were regarded as equal for
the group agreement analysis by Cohen’s kappa (see below).
Statistical analysis
Statistical analyses were performed using commercially
available software (GraphPad Prism5, Graph Pad Soft-
ware, San Diego, CA, USA, SPSS 24.0 for Windows,
SPSS Inc., Chicago, IL USA, G*-Power Version 3, Hein-
rich Heine University, Düsseldorf, Germany). Cortisol
values were tested for normality by the d’Agostino and
Pearson omnibus normality test. As the data were not
normally distributed, ranges and median values are re-
ported. The Wilcoxon signed rank test was used to
examine the difference between the paired measure-
ments. The degree of agreement between group assign-
ments was quantified by Cohen’s kappa. Differences
were considered significant at p < 0.05.
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